MedTrace Logo

Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial

NCT07485569 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-06-22

No results posted yet for this study

Summary

This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.

Conditions

  • Thyroid Cancer Stage IV
  • Anaplastic Thyroid Cancer
  • Differentiated Thyroid Cancer
  • Poorly Differentiated Thyroid Carcinoma

Interventions

COMBINATION_PRODUCT

Personalised treatment

The therapy will consist of (one or more) approved drugs.

Sponsors & Collaborators

  • Maastricht University

    collaborator OTHER

  • EU Horizon

    collaborator UNKNOWN

  • Horizon Europe

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Romana Netea-Maier · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-06-01
Completion
2027-09-01

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07485569 on ClinicalTrials.gov